mover and shaker
A Houston-based preclinical artificial heart device company has a new head honcho as it grows its team and further develops its technology.
BiVACOR named Thomas Vassiliades as CEO effective immediately. He replaces the company's founder, Daniel Timms, in the position. BiVACOR is on track to head toward human clinical trials and commercialization, and Vassiliades is tasked with leading the way.
“BiVACOR led an extensive CEO search, and Tom was the clear choice given his experience, background, leadership style, and exceptional track record,” says Timms in a news release. “Tom has the skillset and credibility to guide BiVACOR through its next chapter of transformation and advancement as we undertake the next stage of clinical activities leading up to First in Human early feasibility studies.”
Vassiliades has over 30 years of experience within the medical device industry as well as cardiothoracic surgery. He was most recently the general manager of the surgery and heart failure business at Abiomed and held several leadership roles at Medtronic. Dr. Vassiliades received his MD from the University of North Carolina, and his MBA was achieved with distinction at Emory University.
“I am excited and honored to join the BiVACOR team, working closely with Daniel and the entire team as we look forward to bringing this life-changing technology to the market,” says Dr. Vassiliades in the release. “Throughout my career, I’ve been guided by the goal of bringing innovative cardiovascular therapies to the market to improve patient care and outcomes – providing solutions for those that don’t have one. BiVACOR is uniquely well-positioned to provide long-term therapy for patients with severe biventricular heart failure.”
Timms will take over BiVACOR's technical team working on the Total Artificial Heart system as CTO. The device, billed as the first long-term therapy for patients with severe heart failure, is an implantable artificial heart based on rotary blood-pump technology. Similar in size to an adult fist, it is small enough to be implanted in many women and some children yet capable of delivering enough cardiac power to a man who's exercising. Unlike the two-chamber human heart, BiVACOR's device features a single chamber.
The medical device company, which has operations in Houston and Australia, recently announced the addition of eight new employees doubling their team. The growth comes following its series B raise last year.
“It is a testament to the great progress the team has made and to the importance of the unmet clinical need addressed by the Total artificial Heart technology," Timms says on the appointment of Vassiliades. "We look forward to Tom’s leadership as BiVACOR navigates the path to commercialization.”